Assembly Biosciences (ASMB) Stock Price, Quote & News

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 509 4583

Website: www.assemblybio.com

Address:

Two Tower Place, 7th Floor, South San Francisco, United States

Zonata Jan. 7 at 1:58 AM

$ASMB key areas for retracement. No bad news, so it should be a great time to buy back shares. The story is intact and the news were peachy.

0 · Reply

Poldi2021 Jan. 6 at 8:20 PM

$ASMB huge buy of 17.000 Shows 👏👏

1 · Reply

Poldi2021 Jan. 6 at 8:18 PM

$ASMB yeah do it..have a great time👏

0 · Reply

ShinnosukeNohara Jan. 6 at 8:16 PM

$ASMB Short it till next Monday😄

0 · Reply

ShinnosukeNohara Jan. 6 at 6:30 PM

$ASMB Gilead executives right now..

1 · Reply

Jkwran69 Jan. 6 at 5:57 PM

$ASMB we've had good news lately so why the daily drops in SP?

1 · Reply

DummiesNixGerafft Jan. 6 at 3:17 PM

Customer first, all information exclusively for our NGC members. Ach ne warte, nur wer noch ne extra Gebühr bezahlt, bekommt beim SD Verein alle Infos. lol. Was einen da erreicht ist ja unfassbar. Es gibt jetzt einen NGC+ 🤣 wohl nur ein paar Tausender extra. Geheimtipp $ASMB -50%

0 · Reply

ShinnosukeNohara Dec. 30 at 8:04 PM

$ASMB

0 · Reply

BillionerOfKing Dec. 30 at 1:53 AM

$ASMB Current Stock Price: $33.44 Contracts to trade: $35 ASMB Jan 16 2026 Call Entry: $0.50 Exit: $0.83 ROI: 66% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

jjokerst Dec. 27 at 6:45 PM

$GILD and $ASMB are co opting research for HSV-1 and HSV-2 (herpes) cure. Recent results showing highly antiviral activity with 94% reduction in results compared to placebo.

0 · Reply

Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes

GILD

Dec 8, 2025, 8:37 PM EST - 4 weeks ago

Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript

Dec 8, 2025, 4:05 PM EST - 4 weeks ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes

Nov 10, 2025, 4:05 PM EST - 2 months ago

Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates

Nov 7, 2025, 8:00 AM EST - 2 months ago

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Assembly Biosciences Announces Upcoming Investor Conference Participation

Oct 10, 2025, 8:00 AM EDT - 3 months ago

Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe

Sep 29, 2025, 7:11 AM EDT - 3 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ATRA CORT

Aug 8, 2025, 4:54 PM EDT - 5 months ago

Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts

Aug 8, 2025, 8:05 AM EDT - 5 months ago

Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

Aug 8, 2025, 8:00 AM EDT - 5 months ago

Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Jul 26, 2025, 3:00 AM EDT - 5 months ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

Jun 30, 2025, 8:00 AM EDT - 6 months ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 25, 2025, 8:00 AM EDT - 6 months ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

May 27, 2025, 4:05 PM EDT - 8 months ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 8 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 7, 2025, 8:00 AM EDT - 8 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Apr 9, 2025, 2:00 AM EDT - 9 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Mar 20, 2025, 4:05 PM EDT - 10 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Feb 26, 2025, 8:00 AM EST - 11 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 20, 2025, 8:00 AM EST - 11 months ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Dec 26, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Feb 8, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Jan 4, 2024, 8:00 AM EST - 2 years ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Nov 10, 2023, 4:05 PM EST - 2 years ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 8, 2023, 8:00 AM EST - 2 years ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Oct 17, 2023, 7:00 AM EDT - 2 years ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 3 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Jan 17, 2023, 7:00 AM EST - 3 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Oct 24, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Zonata Jan. 7 at 1:58 AM

$ASMB key areas for retracement. No bad news, so it should be a great time to buy back shares. The story is intact and the news were peachy.

0 · Reply

Poldi2021 Jan. 6 at 8:20 PM

$ASMB huge buy of 17.000 Shows 👏👏

1 · Reply

Poldi2021 Jan. 6 at 8:18 PM

$ASMB yeah do it..have a great time👏

0 · Reply

ShinnosukeNohara Jan. 6 at 8:16 PM

$ASMB Short it till next Monday😄

0 · Reply

ShinnosukeNohara Jan. 6 at 6:30 PM

$ASMB Gilead executives right now..

1 · Reply

Jkwran69 Jan. 6 at 5:57 PM

$ASMB we've had good news lately so why the daily drops in SP?

1 · Reply

DummiesNixGerafft Jan. 6 at 3:17 PM

0 · Reply

ShinnosukeNohara Dec. 30 at 8:04 PM

$ASMB

0 · Reply

BillionerOfKing Dec. 30 at 1:53 AM

0 · Reply

jjokerst Dec. 27 at 6:45 PM

$GILD and $ASMB are co opting research for HSV-1 and HSV-2 (herpes) cure. Recent results showing highly antiviral activity with 94% reduction in results compared to placebo.

0 · Reply

DLTT4489 Dec. 26 at 5:39 PM

$ASMB holding nice 👌 👍

0 · Reply

ShinnosukeNohara Dec. 26 at 2:12 PM

$ASMB 2 A.I. generated bullshit messages below me😄

1 · Reply

BoundaryBaron Dec. 26 at 7:14 AM

$ASMB Volatility reflects unresolved questions around how strategy converts into durable results. Strategic direction should avoid unnecessary detours. If milestones track on schedule, sentiment can re-rate faster than fundamentals. Investors will demand validation before expanding exposure.

0 · Reply

DerivativeDomain Dec. 25 at 4:49 PM

$ASMB What matters next is the company’s ability to build a predictable delivery rhythm. Competitive differentiation needs clearer proof points. Any disconnect between guidance and outcomes will magnify skepticism. Over time, credibility will hinge on repeatable performance.

1 · Reply

onemillion2012 Dec. 24 at 10:04 AM

$LITS $ASMB i think The German master Alexander S. Have sild out of both Asmb and lits. Can be no other then margin call. He paid top Dollar for $LITS and sold out at forever low price

0 · Reply

alby80 Dec. 23 at 10:08 PM

$ASMB Is this news positive or negative? I read it as positive but it went down? Did I read the announcement wrong?

2 · Reply

RunnerSignals Dec. 23 at 9:01 PM

$NOW $TEM $FLUT $ASMB $KYMR are trending! From AI healthcare to gaming and biotech these top upgrades could be your next big move. see why inside https://stocksrunner.com/news/2025-12-23-stock-upgrades-today-highlight-top-picks

0 · Reply

Poldi2021 Dec. 23 at 8:40 PM

$ASMB relax and hold guys..everything allright

0 · Reply

ShinnosukeNohara Dec. 23 at 7:47 PM

$ASMB this stock is so easy to manipulate 👌

1 · Reply

onemillion2012 Dec. 23 at 1:20 PM

$ASMB what is that 600,000 block shares that just wen't though

0 · Reply

StocktwitsNews Dec. 22 at 10:19 PM

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs $ASMB $GILD https://stocktwits.com/news/equity/markets/assembly-biosciences-stock-jumps-after-wall-street-says-gilead-opt-in-significantly-derisks-genital-herpes-programs/cLeFH3TREuT

0 · Reply

ShinnosukeNohara Dec. 22 at 9:14 PM

$ASMB https://www.businesswire.com/news/home/20251222000246/en/Gilead-Sciences-to-Present-at-Upcoming-Investor-Conference

0 · Reply

Market Cap	533.75M
Revenue (ttm)	28.52M
Net Income (ttm)	-40.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.88%
Debt to Equity Ratio	0.00

Volume	93,000
Avg Vol	131,326
Day's Range	N/A - N/A
Shares Out	15.82M
Stochastic %K	3%
Beta	1.14
Analysts	Strong Sell
Price Target	$45.80